Coronary Heart Disease, Susceptibility to, 1 Clinical Trial
Official title:
The Surem TRAF3IP2 Level and Atherosclerotic Plaque Development in Human
To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human
Previous study had concluded that TRAF3IP2 plays a causal role in atherosclerotic plaque development and vulnerability in mice. However, no human data was available. In the present study, patients who receive coronary angiography will be enrolled. Their surem TRAF3IP2 levels will be tested using ELASA. The association of surem TRAF3IP2 levels with the atherosclerotic plaque will be evaluated. ;